Semisynthesis and Pharmacology of Anidulafungin

Anidulafungin, marketed under the brand name Eraxis among others, is a semisynthetic echinocandin employed as an antifungal agent. When used in combination with voriconazole, Anidulafungin may also be applied in the treatment of invasive Aspergillus infections. As a member of the echinocandin class of antifungal drugs, its mechanism of action involves the inhibition of (1→3)-β-D-glucan synthase, a key enzyme required for fungal cell wall synthesis. Furthermore, Anidulafungin is included as a therapeutic alternative on the World Health Organization’s List of Essential Medicines.

Figure1: Picture of Anidulafungin

History

Anidulafungin was initially discovered in the laboratories of Eli Lilly by researchers Turner and Debono, after which it was licensed to Vicuron Pharmaceuticals, which subsequently submitted the drug to the U.S. Food and Drug Administration (FDA) for evaluation. Following Pfizer's acquisition of Vicuron Pharmaceuticals in the fall of 2005, the development and commercialization rights for Anidulafungin were transferred to Pfizer. The drug ultimately received formal approval from the FDA on February 21, 2006.

Semisynthesis

Anidulafungin is produced through a semisynthetic process. The starting material is echinocandin B, a lipopeptide obtained by fermentation of Aspergillus nidulans or the closely related species A. rugulosus. This intermediate undergoes enzymatic deacylation—catalyzed by a deacylase enzyme derived from the bacterium Actinoplanes utahensis—which cleaves the linoleoyl side chain. Subsequently, through three synthetic steps that include chemical reacylation, the final active compound, Anidulafungin, is obtained. [1]

Purification Method

A patent has disclosed a purification method for the echinocandin antifungal agent Anidulafungin. The procedure comprises the following steps: (1) Preparation of the dry sample – the crude Anidulafungin is dissolved in an organic solvent, silica gel is added after complete dissolution, and the mixture is homogenized and dried to obtain a dry loaded sample; (2) Pressurized elution – the dry sample is evenly packed on top of a chromatography column pre‑filled with silica gel, followed by pressurized elution with an elution solvent while monitoring the process using high‑performance liquid chromatography (HPLC), and fractions containing Anidulafungin with purity greater than 98% are collected; (3) Concentration – the collected fractions with Anidulafungin content exceeding 98% are concentrated to dryness, yielding a purified product with purity above 98%. This method utilizes column chromatography, which is simple to operate and requires low equipment cost. The use of low‑toxicity, low‑boiling organic solvents as the eluent simplifies subsequent recovery and reduces environmental pressure. Additionally, the process features short purification time, excellent separation efficiency, high recovery yield, and is well‑suited for large‑scale industrial production. [2]

Indications

Anidulafungin is indicated for the treatment of candidemia and other invasive Candida infections, including intra‑abdominal abscess and peritonitis, as well as for esophageal candidiasis. However, Anidulafungin has not been evaluated in clinical studies for infections such as endocarditis, osteomyelitis, or meningitis caused by Candida, nor has it been sufficiently studied in neutropenic patients to establish its efficacy in this specific population.

Pharmacology

Anidulafungin exhibits a distinct metabolic profile compared to other antifungal agents, as it undergoes gradual chemical degradation into inactive forms under physiological pH and temperature conditions. Since its clearance does not depend on enzymatic metabolism or hepatic/renal excretion pathways, the drug can be administered safely to patients with varying degrees of hepatic or renal impairment. With regard to its pharmacokinetics, Anidulafungin is not substantially metabolized by the liver. Instead, it is slowly transformed via chemical hydrolysis into an open-ring peptide derivative that lacks antifungal activity. The drug has an elimination half-life of approximately 27 hours. Approximately 30% of the administered dose is excreted in the feces, of which about 10% remains in the unmetabolized form, while less than 1% is eliminated through renal excretion in the urine.[3]

Mechanism of Action

Anidulafungin functions by specifically inhibiting glucan synthase, a key enzyme responsible for the biosynthesis of β-D-glucan, which constitutes an essential structural component of the fungal cell wall. Since glucan synthase is absent in mammalian cells, Anidulafungin offers a highly selective and attractive target for antifungal therapy, thereby minimizing potential toxicity to human host tissues.

Reference

[1] Denning D W. Echinocandins and pneumocandins--a new antifungal class with a novel mode of action[J]. The Journal of antimicrobial chemotherapy, 1997, 40: 611-614.

[2] Xing, Z. T.; Yan, G. T.; Chen, F.; et al. A purification method for the echinocandin antifungal drug anidulafungin: CN201310146413.6[P].

[3] Kofla G, Ruhnke M. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis-review of the literature[J]. European journal of medical research, 2011, 16: 159.

You may like